Oslo, Norway, September 11, 2023 - Nykode Therapeutics ASA (OSE: NYKD), a
clinical-stage biopharmaceutical company dedicated to the discovery and
development of novel immunotherapies, today announced that its Chief Executive
Officer, Michael Engsig and Chief Business Officer and Co-founder Agnete
Fredriksen, will present and host 1x1 meetings at the H.C. Wainwright 25th
Annual Global Investment Conference in New York on Monday, September 11, 2023,
at 7:00 a.m. ET / 1.00 p.m. CET.

To schedule a one-on-one meeting with the Company, please contact
meetings@hcwco.com at H.C. Wainwright.

The presentation slides will be available in the Investors section of the
Company's website at
https://nykode.com/investors/financial-reports-and-presentations/. 


About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of novel immunotherapies for the treatment of
cancer, infectious diseases and autoimmune diseases. Nykode's modular vaccine
technology specifically targets antigens to Antigen Presenting Cells, which have
been shown to induce broad, strong and long-lasting antigen specific immune
responses which correlates with clinical responses.

Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive safety and efficacy results from its Phase 2 trial for the
treatment of cervical cancer